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ABO and platelet transfusion
therapy
L.COOLING
It is appropriate to take steps to optimize the efficacy
and safety of transfusion therapy. Perhaps we should
study the role of ABO compatibility in platelet
transfusion therapy more carefully so that further
improvements may be made.
Scott Murphy, Transfusion Editorial 19881
The relative importance of ABO compatibility and
platelet transfusion has been a matter of debate for
more than 50 years. Since the early studies of Richard
Aster,2 it has been recognized that transfusion of ABO-
incompatible platelets can be associated with decreased
platelet increments after transfusion. In the last 10 to 15
years, there has been increasing discussion and concern
regarding minor-incompatible platelet transfusions that
have been linked to acute hemolytic transfusion
reactions, venoocclusive disease, and increased
morbidity in allogeneic transplants.3–5 This review will
briefly summarize the biochemistry, regulation, clinical
practice, and considerations surrounding ABO
compatibility and platelet transfusions.
ABO Glycoconjugates on Platelets
ABO antigens are expressed on several endogenous
platelet glycoproteins and glycolipids. Platelet-specific
glycoproteins (GP) known to express ABH antigens
include GPIIb/IIIa, GPIb/IX, GPIa/IIa, GPIc, GPIV, GPV,
CD31 (PECAM), and CD109.6–10 GPIIb/IIIa, in
particular, appears to be a significant contributor and
determinant of ABH expression on platelets. The
GPIIb/IIIa complex numbers nearly 250,000 molecules
per platelet and possesses between five and eight bi-
and triantennary N-glycans capable of displaying ABH
epitopes.10,11 GPIIb/IIIa is the major target of human
anti-A and anti-B in vitro.7 Likewise, a linear correlation
between A antigen on GPIIb and intact platelet
membranes (R = 0.91) was reported by Cooling et al.10
Translocation and ongoing synthesis of GPIIb/IIIa may
also contribute to the increased antigenicity of
platelets during in vitro storage. Julmy et al.12 reported
a nearly 50 percent increase in ABH expression on
platelets during routine storage, accompanied by
evidence of platelet activation and translocation of α-
granule proteins (including GPIIb/IIIa) to the platelet
membrane. More recent studies in platelet proteomics
and the platelet transcriptome suggest ongoing
translation and synthesis of GPIIb/IIIa during storage as
well.13
Platelets also express a small population of
glycosphingolipids with ABH activity. Early studies
showed the ability of platelets to adsorb and elute
soluble type 1 chain ABH and Lewis antigens from
plasma, leading to the speculation that all ABH-active
glycolipids were entirely of exogenous origin.14
Subsequent studies using chain-specific monoclonal
antibodies showed that platelets expressed type 2
chain glycolipids and glycoproteins, indicating that
most ABH-active glycolipids were of megakaryocyte or
endogenous origin.6,10,15,16 This was confirmed by
Cooling et al.10 who identified ABH-active glycolipids in
platelets from Le(a+b–) individuals who should lack
soluble type 1 chain antigen. The ABH-active
glycosphingolipids of platelet are predominantly
simple, linear structures (6–8 oligosaccharides)
although a few complex sialylated structures are
present.10,17,18 In group A1 donors, type 4 chain or
globo-ABH structures have also been identified.16,19
This is in sharp contrast to RBCs,which express a rich
variety of ABH-active glycolipids, including complex,
highly branched polyglycosylceramides.19,20 The
contribution of ABH-active glycolipids to overall ABH
expression on platelets appears to be minor.10
ABO Expression on Megakaryocytes
Although recent studies indicate some residual
protein synthesis in young platelets,13 the majority of
ABH synthesis occurs at the level of the megakaryocyte.
ABH antigens have been identified on immortalized
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megakaryoblastic cell lines and cultured bone marrow
megakaryocytes.21,22 In the latter, ABH exhibits
developmental and distinct clonal variation, with
individual megakaryocyte colonies differing widely in
the amounts of A, B, and H antigens expressed.21 Clonal
variation may underlie the heterogeneity observed on
circulating platelets.10,21 In addition, there is a direct
correlation between A and H on megakaryocytes, with
colonies either positive or negative for both H and A
antigens. Cooling et al.10 subsequently showed a direct,
linear relationship between H and A antigens on
circulating platelets by two-color flow cytometry (R =
0.95). On the basis of their findings,Dunstan et al.21 and
Cooling et al.10 speculated that H antigen synthesis is a
rate-limiting step regulating ABH expression in
megakaryocytes and platelets.
H antigen appears to be developmentally regulated
in early hematopoiesis. H, LeY, and FUT1 mRNA are
expressed by CD34+ cells and likely early mega-
karyocyte progenitors.22–24 During megakaryocytic
differentiation, both H and LeY antigens are
progressively lost with increasing ploidy and
proplatelet formation.22 The presence of H antigen on
early megakaryocyte progenitors may facilitate
adhesion to stromal fibroblasts,25 a necessary step for
megakaryocytic preservation and expansion.26,27
Schmitz and colleagues25 were able to inhibit
megakaryocyte adhesion to stromal fibroblasts with
fucosylated bovine albumin, soluble H antigen, and
fucose-specific lectins. Although the precise lectin-
ligand pair involved in fucose-mediated adhesion is not
yet identified, several megakaryocyte proteins critical
to megakaryocyte development and adhesion can
express ABH antigens, including α4β1,α5β1 GPIIb/IIIa,
GPIb, and PECAM.28,29 H antigen on integrins may be
particularly important: H and LeY expression are
associated with increased fibronectin binding, cell
adhesion, and resistance to apoptosis in epithelial
tissues.30–32 An increase in fucose-mediated adhesion,
with delayed megakaryocyte maturation, may account
for delayed platelet engraftment in some group O
autologous transplant patients.33
Platelet ABO and Genetic Variation
There are dramatic differences in the amount of
ABO expressed on platelet membranes between
individual donors. Genetic differences in ABO
glycosyltransferase alleles underlie some of these
differences. In group A donors, expression of A antigen
on platelet membranes, glycoproteins, and glycolipids
is linked to an A1 RBC phenotype.
7,10,16,34,35 In contrast,
A2 donors express little or no A antigen and can be
considered group O compatible.10,35 Lewis and
secretor phenotype appear to play little role in either
the presence or strength of ABO antigens on platelets:
A2, Le(a–b+) donors are also negative for A antigen by
flow cytometry.10 Because they lack A antigen on
platelets,A2 individuals can develop an anti-A1 and ABH-
specific refractoriness.34
Among group A1 donors, there is a wide variation in
platelet A expression (Fig. 1E).7,10,35 In individual
donors, the percentage of circulating platelets positive
for A antigen by two-color flow cytometry (CD41+,
HPA+) can range from less than 5 percent to 87
percent (population average = 40%).10 Even within a
single donor, there is distribution of positive and
negative platelets (Fig. 1B). Despite the latter, the
average percentage of platelets positive for A antigen is
relatively stable over time and may represent a unique,
donor-specific characteristic.10 As shown in Figure 1F,
the percentage of A antigen–positive platelets, in paired
samples (S1, S2) collected from the same donor at two
separate times, is nearly identical.
Unlike A1 donors, most group B donors weakly
express ABO antigens on platelets.7,10,36 In our own
studies, only 20 percent of platelet donors were
positive for B antigen by flow cytometry.10 Similar
findings are observed with platelet crossmatching, in
which 83 to 100 percent of group B platelet donors
were crossmatch-compatible with group O and group
A serum, respectively.36 Despite these results, group B
antigen can be identified on platelet glycoproteins and
glycosphingolipids in most group B donors (80–90%).10
The density or antigenicity on individual platelet
glycoproteins, however, may be decreased relative to
most A1 donors (< 50%),on the basis of solid phase and
radioimmunoassay studies with human anti-B.7
High-Expressor Phenotype
Approximately 4 to 8 percent of A1 and B donors
are ABO high expressors (HXP),defined as a 2- to 3-fold
increase in platelet ABO expression (> 2 SD).10,34,37 ABO
HXPs can be further subclassified as type 1 and type 2
on the basis of their flow cytometry profiles.10,35 Type
1 donors demonstrate a bimodal population of strongly
positive and moderately to weakly positive platelets,
akin to the bimodal population of positive and negative
platelets observed in most A1 donors (Fig. 1B). In
contrast, type 2 donors have an essentially uniform
population of strongly positive platelets (Fig. 1C).
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Transfusion of ABO-HXP platelets to a group O
recipient has resulted in profound transfusion failures,
even with HLA-matched platelets.37 Platelets fromABH-
HXP donors should be reserved for ABO-identical
recipients only.
The molecular origin of the ABO-HXP phenotype is
still unknown. Family studies indicate that the trait is
autosomal dominant.37 There is no relation between
the ABO-HXP and a secretor phenotype.10,37 Elevated
ABO glycosyltransferase activity has been noted in the
sera of some donors35,37;however, sequencing studies of
the ABO gene have not revealed any mutations.35
Cooling et al.10 suggested that the ABO-HXP might
represent clonal upregulation of the H or FUT1 gene.
Future studies focusing on transcriptional regulation of
H and ABO genes in megakaryocytes, including
epigenetic phenomena, may eventually unravel the
genetic mystery behind the ABO-HXP phenotype.
ABO Compatibility and Platelet Transfusion
Response
The influence of platelet ABO and the post-
transfusion response is highly variable, reflecting both
donor and recipient factors. Recipient factors that
may influence the transfusion response include ABO
type, sex, and parity; isohemagglutinin titers; and
immunosuppressive drugs. Platelet and donor factors
can include ABO type (A1, A2, B), donor-specific
differences in ABO strength, platelet activation, and
storage time. As noted in the previous section, ABO
expression varies widely between individual donors
and ABO types.10,35
Fig. 1. Donor-specific differences in ABO expression. A–C: Sample histograms of platelets from A2 (A),A1 (B), and an A1 high-expressor donor (A1-HXP,C).
Platelets were dual labeled with a platelet-specific monoclonal antibody (CD41) and the anti-A lectin,Helix pomatia (HPA). For analysis, platelets
were gated on CD41 and the percent CD41+, HPA+ platelets determined by two-color flow cytometry. D and E: Expression of A antigen on
platelets in A2 (D) and A1 donors (E). Note the wide distribution of A antigen-positive platelets in A1 donors, including 5 percent with high
expression (A1-HXP). Little or no A antigen was detected in A2 and 6 percent A1 donors. F: Stable expression of A antigen on platelets.The percent
HPA+ platelets in individual donors was compared in two different samples (S1, S2) at 1- to 4-month intervals.
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The earliest studies examining the effect of ABO
and platelet transfusion were performed by Richard
Aster in 1965.2 Using radiolabeled platelets,Aster et al.
reported a 60 to 90 percent decrease in the 1-hour
posttransfusion platelet increments after transfusion of
group A and AB platelets to group O recipients. This
was substantiated in an elegant study by Jimenez et
al.,38 who compared the posttransfusion recovery in
paired recipients of split apheresis products from the
same donor. The authors found similar platelet
recoveries when both recipients were ABO compatible
with the donor (R = 0.8); however, transfusion to an
ABO-incompatible recipient was accompanied by
marked, significant decreases in posttransfusion
recovery at 1 (p < 0.001), 4 (p < 0.004), and 24 hours
(p < 0.04). Improved platelet recovery with ABO-
identical and ABO-compatible platelets has also been
observed in large clinical trials, including the Trial to
Reduce Alloimmunization to Platelets.39,40
There are several examples of platelet
refractoriness caused by ABO in the literature.34,37,41,42
In a small randomized trial of ABO-identical and ABO-
unmatched platelets, the vast majority of patients
receiving ABO-unmatched platelets had a decrease in
posttransfusion recovery, with 37 percent having clear
evidence of ABO-specific refractoriness.43 In a second
study, clinical refractoriness was significantly higher in
patients receiving ABO-mismatched platelet trans-
fusions (69% vs. 8%) and was typically heralded by a
sudden acute rise in isoagglutinin titers.44 In a more
recent study, ABO-incompatible platelet transfusions
stimulated isohemagglutinin titers in 40 to 50 percent
of patients after only one to two transfusions.45 Not
surprisingly, patients with documented ABO refrac-
toriness often have high titer isohemagglutinins
(> 1:500–1:1000). Platelet-associated antibody in these
patients can approach 30,000 molecules of IgG per
platelet after transfusion of an ABO-incompatible
platelet.7 In contrast, IgM binding to platelets is
minimal (< 350 molecules/platelet).7
Although most case reports and studies have
focused on ABO major-incompatible transfusions, poor
platelet recoveries and clinical refractoriness can also
be observed with ABO minor-incompatible or out-of-
group transfusions.39,46,47 According to one study,
plasma-incompatible transfusions were associated with
an 18 percent decrease in posttransfusion recovery
when compared with ABO-identical transfusions.39 The
adverse effect of incompatible-plasma infusion may be
caused by the formation of immune complexes
composed of donor ABO antibodies and soluble ABO
substances in blood.46,47 These immune complexes may
then bind to either complement or Fc receptors on
platelets, leading to accelerated immune clearance.46
Among refractory patients, 40 percent have elevated
levels of circulating immune complexes.Among group
A patients transfused with ABO-mismatched platelets,
80 percent had evidence of immune complexes
containing IgG anti-A of donor origin.47
Alloimmunization
Routine transfusion of ABO-incompatible platelets
can promote HLA alloimmunization. In randomized
trials, patients routinely transfused with ABO-
mismatched platelets were more likely to develop both
HLA and platelet-specific antibodies, accompanied by
an earlier onset and higher incidence of clinical
platelet refractoriness.44,48 ABO incompatibility can
also act synergistically with HLA and crossmatch
compatibility to further decrease the posttransfusion
response.36,39,49
In a retrospective study of 51 refractory patients,
Blumberg and colleagues39 demonstrated decreased
platelet recoveries in 60 percent of all ABO-incompatible
transfusions, regardless of platelet crossmatch results.
Among patients receiving crossmatch-compatible
platelets, an ABO mismatch was associated with a 40
percent decrease in posttransfusion recovery. The
impact was more dramatic with ABO-mismatched,
crossmatch-incompatible platelets (85% decrease).
Overall, ABO-identical platelets were clinically equiv-
alent or better than ABO-incompatible, HLA-matched,
or crossmatch-compatible platelets.
The synergism between ABO, HLA, and clinical
refractoriness can have direct economic conse-
quences. The University of Rochester reported a 20
percent decrease in platelet utilization and a 40
percent decrease in HLA-matched platelets after
instituting a policy requiring ABO-identical platelets
for their leukemic patients.50–52 This policy has led to
improved survival and decreased morbidity based on
the results of a small randomized trial (n = 40 patients).
Leukemia patients who received only ABO-identical
platelets had longer remissions and improved survival
relative to patients transfused with ABO-nonidentical
platelets.53 There was also a decrease in major bleeding
episodes (5%) with 70 percent of patients having no
evidence of clinical bleeding.54
The impact and cost effectiveness of ABO
compatibility in other patient populations is still
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debated. In a retrospective study of cardiovascular
surgery patients, Blumberg et al.55,56 found that patients
transfused with ABO-identical platelets had decreased
morbidity and mortality, as measured by fever,
antibiotic usage, transfusion support, and hospital
admission days. These differences corresponded to an
average savings of $10,000 to $15,000 in direct costs
and patient charges. These findings have been
challenged by Lin et al.,57 who found no significant
differences in either morbidity or mortality in a similar
group of cardiovascular patients. In the latter study, the
authors concluded that the use of ABO-nonidentical
platelets is “an acceptable and safe practice” in surgical
patients.
ABO, Platelets, and Transplantation
There is increasing concern regarding platelets and
ABO compatibility in bone marrow transplant patients,
particularly in patients receiving ABO-incompatible
allogeneic transplants who have complex transfusion
needs.58–60 Because of the adverse effect of ABO
incompatibility on erythroid engraftment, it is a
practice to transfuse plasma and platelets that are
compatible with the stem cell or marrow donor.61 In
most instances, this may require transfusion of an ABO
major-incompatible or minor-incompatible platelet.
Several studies have linked increased platelet
transfusions and transfusion of plasma-incompatible
platelets with increased morbidity, venoocclusive
disease, multiorgan failure, and death.4,5,62 Organ
dysfunction usually follows a 1- to 2-week period of
rising platelet transfusion requirements, suggesting a
causal relationship.62
It is hypothesized that donor ABO antibodies may
result in immune complex formation in the host,
leading to systemic inflammation. Alternatively, pas-
sively infused antibodies may recognize and bind ABO
antigens on endothelial cells, leading to an increase in
treatment-related toxicity and microvasculature
damage.5,62 Some transplant centers provide ABO-
compatible, plasma-reduced products for their ABO-
mismatched, allogeneic transplant patients.4,5
Little is known regarding the effect of ABO-
incompatible platelets in the setting of solid organ
transplantation, particularly ABO-incompatible kidney
and heart transplants. Current regimens require several
rounds of plasmapheresis or immunoadsorption
combined with immunosuppression to decrease iso-
agglutinin titers.63,64 To avoid passive transfusion of
isoagglutinins harmful to the graft, platelets should be
plasma compatible with the donor in the immediate
perioperative period. However, transfusion of ABO
major-incompatible platelets could also present
problems, particularly postoperatively. As discussed in
a previous section, ABO-incompatible platelets can
stimulate isoagglutinin titers in some recipients.44,45 In
one small study,ABO-incompatible platelet transfusions
from the intended kidney donor were used to test the
immune responsiveness of the recipient.45 Of seven
patients, one developed HLA antibodies and three
demonstrated a rise in isohemagglutinin titers. Only
patients with little or no response to platelet
transfusion underwent transplantation with good
outcomes 4 to 7 years after transplant.
Acute Hemolytic Transfusion Reactions
Currently, the greatest discussion around ABO and
platelet transfusion is the risk of acute hemolytic
transfusion reactions (HTR) with ABO minor-
incompatible or out-of-group platelets (Table 1).65–88
Although most queried transfusion services provide
ABO-identical platelets or plasma-compatible platelets
when available,89,90 it is estimated that 10 to 40 percent
of transfusions are plasma incompatible with the
recipient.73,76 The most common reasons for trans-
fusing out-of-group platelets are limited inventory of
ABO type-specific platelets and HLA-matched platelets
and to minimize product wastage.90 To date, only a
handful of severe HTRs with platelet transfusion have
been reported in the literature and Internet chat
rooms.
Despite the transfusion of more than 2 million
platelet concentrates per year (including potentially
200,000 to 400,000 out-of-group transfusions), the true
risk and incidence of hemolysis with plasma-
incompatible platelet transfusions is still a matter of
conjecture. Facility-specific rates for platelet-associated
HTR range from less than 1 in 1000 to less than 1 in
25,000 for all platelet transfusions and less than 1 in
100 to less than 1 in 9000 for minor-incompatible
platelet trans-fusions.73,76,91,92 This wide range may
reflect heterogeneity in the type of platelet products
transfused (apheresis vs. random), index of clinical
suspicion, and severity of the reaction. On the basis of
the yearly number of transfusions in the United States,
it is clear that severe HTRs after out-of-group platelet
transfusions are relatively rare events. However, mild
hemolysis may be more common than appreciated.
Oza et al.92 found mild to moderate evidence of
hemolysis with elution of ABO antibodies in 1 to 2
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Table 1. Acute hemolytic transfusion reactions with platelets
Donor ABO type Platelet donor and product Outcome†
Reference Age* Sex Diagnosis Patient Donor(s) Saline AHG Product Volume ↓Hb (%)
Zoes65 44 F AML-M4 AB O Anti-A:256‡ NR Random-pool 500 mL NR
Anti-B:64
McLeod66 45 M AML-M6 A O 1280 10,240 Random-pool 50 6 (43%)
O 640 10,240 Random-pool 50
Conway67 15 F Transplant A O 8192 NR Apheresis-HLA 200 NR
Pierce68 2.5 F ALL A O 512 32,000 Apheresis 200 5.8 (50%)
58 F Angioplasty B O 512 16,384 Random 50 6.1 (43%)
Ferguson69 66 M AML A O 256 >4000 Random 50 2.6
Reis70 56 M Aplastic anemia B O NR 4096 Apheresis NR 6.1 (46%)
Murphy71 30 F AML A O 512 2048 Apheresis-HLA 225§ 4.0 (40%)
256 1024 Apheresis-HLA 448§ 5.4 (47%)
Chow72 18 F AML-M4 AB O 1024‡ 520‡ Apheresis, pooled 1200¶ 5.5 (50%)
Mair73 28 M Neuroblastoma A O,A,AB 128 NR Apheresis 225 2.6 (31%)
McManigal74 72 F Cardiac surgery AB O,B,A NR NR Apheresis 3380¶ 
Larsson76 44 F AML A O Anti-A:16384 NR Apheresis 371 2.3 (30%)
Duguid75 0.1 M Cardiac surgery A O NR NR Random-pool 100 4.5 (33%)
0.02 F Cardiac surgery A O NR NR Random-pool 100 NR
Valbonesi77 51 F Breast cancer A O >8000 NR Double apheresis 37 3.5 (40%)
16 F Aplastic anemia A (dry platelet) 37 3.2 (37%)
Sauer-Heilborn78 35 M Transplant B O 4096 NR Apheresis 526 5.3 (50%)
Anonymous79 36 F Hodgkin’s A O NR 2048 Apheresis 214 2.5 (22%)
45 M AML A O NR 4096 Apheresis 241 1.6 (15%)
Gresens80 29 M Trauma A O 1024 1024 Apheresis 260 NR
Ozturk82 21 M RAEB A O NR NR Apheresis 600 5.7 (36%)
Yeast81 0** NR NAIT B O NR NR Apheresis 15 10 (83%)
Anonymous83 NR NR NR AB O NR NR Apheresis NR 5.3 (53%)
Josephson84 Adult NR Leukemia A O 256 8192 Apheresis 50 3
Adult NR Leukemia A O NR 1024 Apheresis 50 3
Angiolillo85 0.7 M Histiocytosis A O 128 NR Apheresis 107 3.5 (47%)
Sapatnekar86 2 F Medulloblastoma A O 2048 16384 Apheresis 145 3.9 (32%)
Sadani87 65 F AML-M0 A O 160 1280 Apheresis NR 3.8 (49%)
Mean 32.5 2403 7162 350 5.8
Range 0–72 128–16,384 1024–32,000 82%-Apheresis 15–3380 1.6–10
AHG = antihuman globulin;ALL = acute lymphocytic leukemia;AML = acute myelocytic leukemia; NAIT = neonatal alloimmune thrombocytopenia; NR = not reported; RAEB =
refractory anemia with excess blasts.
* Age in years.
† Fall in Hb by g/dL and percent decrease (%) from pretransfusion levels.
‡ Isoagglutinin titers in the recipient after transfusion of ABO minor-incompatible platelets.
§ Same HLA-matched donor, transfusions 1 month apart.
¶ Total volume of incompatible plasma infused.
 Active bleeding.
** Intrauterine transfusion.
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percent of all ABO-mismatched apheresis platelets,
which accounted for 6.7 percent of all transfusion
reactions associated with platelets. An increased rate of
adverse reactions with ABO minor-incompatible
transfusions was also noted by Wagner and Adamo.93
Out-of-group platelet transfusions, however, have a
minimal impact on RBC utilization. Two studies have
found no difference in the level of anemia or RBC
utilization in oncology patients receiving plasma-
incompatible transfusions.73,94
A summary of severe HTRs associated with plasma-
incompatible platelets is shown in Table 1. In nearly all
cases, hemolysis followed the transfusion of group O
platelets to a non-group O patient. Clinically, the
unfortunate recipient displayed classic symptoms of an
acute HTR immediately or shortly after transfusion,
leading to rapid recognition and diagnosis. In a few
instances, the diagnosis was only suspected hours or
days later after the onset of hemoglobinemia,
hemoglobinuria, or unexplained anemia.66,68,75,77,85,87
Although most patients recovered with hydration and
supportive care, a handful of deaths are known,
including at least five deaths in the United States.68,78 In
very rare cases, plasma exchange, RBC exchange with
group O RBCs, or both were performed to stem the
hemolysis.77
Laboratory studies in these patients were all
consistent with an acute HTR. Patients’ RBCs typically
became strongly positive in the DAT (IgG, C3) with
elution of ABO antibodies from the RBCs. Laboratory
evidence of intravascular hemolysis was always
present, including an abrupt drop in hemoglobin,
hemoglobinemia, hemoglobinuria, decreased hapto-
globin, spherocytes, hyperbilirubinemia, and elevated
lactate dehydrogenase. Disseminated intravascular
coagulation has been reported in two cases with fatal
outcomes.68,78 The degree of hemolysis can be
impressive, with a drop in hemoglobin ranging from 2
to 10 g/dL. In many cases, the patient will show an
appropriate increment in platelet count after
transfusion.70,74,81 An investigation of the implicated
platelet donors revealed unusually high isoagglutinin
titers in most cases. Several of the group O donors
in published reports were women, and included
a directed donation from a group O mother to her 2-
year-old daughter.68,77 Women with a history of a prior
ABO-incompatible pregnancy are at increased risk for
developing high-titer isoagglutinins.95
Several factors may raise the risk for an HTR after
an out-of-group platelet transfusion. Apheresis
platelets,which contain 200 to 400 mL of plasma from
a single donor, carry a higher risk of causing hemolysis
because of a high-titer donor than do pooled platelets.
This is substantiated by a review of the literature, in
which 23 of 28 (82%) platelet-associated HTRs were
associated with apheresis platelets. This risk is
substantially lessened with pooled platelets because of
the smaller volume of plasma per donor (50 mL),which
is subsequently diluted 4- to 6-fold in the final product.
The use of pooled platelets does not eliminate the risk
of an HTR: four HTRs caused by plasma-incompatible
pooled random platelets have been reported, in two
neonates75 and two adults.65,66 In the latter, two high-
titer donors were pooled and infused.66 The total
volume of ABO-incompatible plasma must also be
considered, including residual plasma present in
transfused group O RBCs.74,87,96 McManigal et al.74
reported severe hemolysis in a patient who received
multiple out-of-group platelet transfusions, resulting in
the transfusion of 3380 mL of incompatible plasma
(106% of patient’s blood volume) during a period of 4
days.74
Patient factors can also contribute to the risk of an
HTR after an ABO-incompatible transfusion. As shown
in Table 1, there is an increased risk of hemolysis when
high-titer isoagglutinins are transfused to group A and
AB recipients (23 of 28)—a finding not surprising to
blood bank staff. Very young children may also be at
increased risk because of their relatively small blood
volume.75,81,85,87 It has been surmised that young
children and nonsecretors may also have an increased
susceptibility because ABO substances capable of
adsorbing and neutralizing ABO antibodies are
decreased in or absent from their blood. Among
published cases, only two investigated the Lewis type
of the recipient.65,78 One recipient was a nonsecretor
[Le(a+b–)])65; however, the second patient was
Le(a–b+),78 suggesting that soluble ABO antigens may
provide only limited protection. Finally, other ill-
defined patient factors could also play a role. Look-
back investigations of two high-titer group O apheresis
platelet donors failed to identify any additional HTRs in
70 prior transfusion recipients.76,78
Approaches to Minimize Hazards of Plasma-
Incompatible Platelet Transfusions
The increased use of apheresis platelets, in which
all the plasma is from a single donor, has heightened
awareness and concern regarding out-of-group
platelet transfusions. Several strategies have been
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implemented. Most transfusion services have policies
dictating the transfusion of ABO-identical or plasma-
compatible platelets when available.89,90 More
proactive strategies are discussed in the following
sections.
Identification of “dangerous donors”
Although only 2 percent of U.S. centers routinely
screen group O donors,90 the practice is relatively
common in Europe.89 With rare exceptions, donors
identified as high titer are still permitted to donate;
however, their products are segregated and labeled as
high titer with a warning to only transfuse to group O
patients. The cost effectiveness of prospective
screening is still unproven, given the relative rarity of
HTR with out-of-group platelets. Sadani et al.87 recently
reported a severe HTR in a group A patient after
transfusion of group O apheresis platelets that initially
tested as low titer by automated testing. Subsequent
testing revealed a high-titer anti-A IgG (Table 1).87 In
contrast, the New York Blood Center, which routinely
screened group O apheresis donors until 1998,has had
no reports of acute HTRs in the 5 years, and more than
25,000 platelet transfusions, since screening was
discontinued.91
A persistent problem that plagues widespread
donor screening is the absence of a recognized
standard method for testing. Several manual and
automated methods are currently used for donor
screening (tube, gel, and solid phase) with a variety of
end point measurements: saline titers, AHG titers, or
hemolysis.84,87,89,97 Even with a single method, there is a
wide range in results (Fig. 2A). Improvements and
increased use of automated blood group testing, such
as gel and solid phase methods,may eliminate much of
the perceived variation in donor isoagglutinin testing
with minimal add-on cost to the final product. This has
been demonstrated in England,where high-throughput
testing is performed using a single plasma or serum
dilution (1 in 100) on an automated blood analyzer.89 A
cost analysis by Emory University, which implemented
testing of all group O apheresis donors by gel method,
estimated an additional cost of $1.20 per apheresis
platelet.84
A second problem with donor screening is
determining a critical titer for “safe” versus high-titer,
“dangerous” donors. As shown in Figure 2A, the
percentage of donors classified as high titer can range
from 3 to 50 percent, depending on the population
tested and the method and critical titer used.76,84,89,97 A
method and critical titer that classifies 40 to 50 percent
of group O donors as high titer could significantly
hamper platelet availability to non-group O patients,
particularly during times of severe shortages. A survey
of current practice shows a cutoff titer of 32 to 200 for
saline testing and 250 to 512 for AHG (Table 2). For
Fig. 2. ABO titers in platelet donors. A: Distribution and variability in
“critical” titers (anti-A) among group O donors. Critical titers by
saline (black circles) and with AHG (squares) for several studies
are shown. B and C: Distribution of anti-A titers in a random
sampling of group O platelet donors (hatched columns) and
group O donors implicated in acute HTRs (black,Table 1). Data
for normal donors taken from Josephson et al.84 by gel. Note that
38 percent of normal donors had titers less than the initial titer
of 32.84 Shown are saline titers (B) and after AHG,C.
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this review, we compared the distribution of
isoagglutinin titers from normal group O apheresis
donors84 and group O donors implicated in HTRs
(Table 1). As shown in Figures 2B and 2C,many of the
cutoffs used (32–64) are quite conservative.
Plasma reduction and platelet additive solutions
A popular method to reduce the risk of ABO HTR
caused by plasma-incompatible transfusions combines
plasma reduction with resuspension in either additive
solutions or group AB donor plasma. In the most
common method, platelet concentrates are prepared
and stored in plasma (30–40%) diluted with a platelet
additive storage solution. Although not licensed in the
United States, a selection of storage solutions are
commercially available or undergoing trials in
Europe.98,99 The use of additive solutions has several
attractive advantages for increasing transfusion safety
including a decreased risk of HTRs as well as TRALI
and allergic and febrile reactions caused by residual
proteins, cytokines, and antibodies present in donor
plasma.93,98–100 In Germany,Wagner and Alamo93 noted
a marked decrease in transfusion reactions with
plasma-reduced platelet concentrates (0%) compared
with routine pooled platelets (27%). Plasma-reduced
platelets reportedly have equivalent posttransfusion
recovery at 1 hour although there is reduced 24-hour
survival.89,98
Plasma reduction and use of platelet additive
solutions may reduce, but will not completely
eliminate, the risk of an acute HTR caused by a high-
titer donor. An enlightening case was recently
published by Valbonesi et al.,77 who described severe
HTRs in two recipients of a split, group O apheresis
unit (Table 1). Apheresis platelets were collected “dry”
with only minimal plasma carryover (74 mL), followed
by resuspension in 400 mL of a platelet additive (T-Sol).
An investigation identified extremely high isoagglutinin
titers (> 8000) in the female donor. The authors noted
that this was the first severe HTR encountered in more
than 16,000 “dry” platelet collections in the last 10
years.
Limiting plasma infusion
Some transfusion services monitor and limit the
total volume of incompatible plasma that a recipient
can receive.79,83,89,90,101 Policies vary between
institutions, ranging from 300 to 500 mL of plasma per
day to 1000 mL of plasma per week (Table 3). In the
United States, approximately 10 percent of polled
institutions (255) limited the amount of incompatible
plasma transfused to adult patients.
In neonates and young children with small blood
volumes, there is a greater concern regarding the risk
of out-of-group platelets.102 As a consequence, most
U.S. hospitals serving neonatal populations provide
only ABO-identical or plasma-compatible platelets
(60%). Very few institutions (1%, 29 institutions) have
policies limiting incompatible plasma infusion to
neonates and children.
Identification of A2 donors as “universal platelet
donors”
Because A2 donors have little or no A antigen on
platelet membranes, they are compatible with group A
and O donors. Donor screening to identify group A2
donors could increase the inventory of group O
compatible from 44 to 52 percent, increasing the
number of apheresis platelets available for platelet
crossmatching,10 which requires ABO compatibility
between donor and patient.36 It could also benefit
selection and survival of HLA-matched platelets.39,40 To
our knowledge, only Norway has policies for
identifying A2 platelet donors as “universal donors.”
89
A2 platelets are also an ideal component for patients
undergoing ABO-mismatched allogeneic bone marrow
transplantation. In ABO major-incompatible transplants,
present guidelines recommend that transfused platelets
be plasma compatible with the marrow or stem cell
donor to minimize delays in erythroid engraftment.46 As
a consequence, platelets will often be ABO
incompatible with the patient’s isohemagglutinins. In
group A (donor) to group O (patient) mismatched
Table 2. Strategies for screening apheresis platelet donors for high-titer
isoagglutinins
Screen Critical %
Country donors Method titer Donors
United States84,90,91 No (2%)90 Tube, gel 1:50–1:200 3–28%
England89 Yes Automated 1:100 3–10%
Tube 1:128
Scotland87 Yes 1:50
Italy89 Yes Gel 1:64
IAT 1:256
Germany89 Yes Tube, saline 1:64 5%
Czech Republic89 Yes Tube, saline 1:64
Norway89 Yes IAT 1:250
Sweden89 Yes Tube, saline 1:100
IAT 1:400
Switzerland89 Yes Hemolysis 1:16
Finland89 Yes Tube, saline 1:32 5.7%
Japan89 Yes IAT 1:512
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transplants, this incompatibility can be overcome by
transfusion of A2 platelets, which are ABO compatible
with the patient’s isoagglutinins and plasma compatible
with the donor graft.10 A2 platelets might also be a
product of choice in group O (donor) to group A
(patient) minor-mismatch transplants. Likewise, A2
platelets are an ideal product for group O patients
receiving group A-incompatible solid organ transplants.
In these patients, transfusion of incompatible plasma
and platelets should be avoided because of the risk of
acute humoral rejection and immune stimulation,
respectively.45,60 It is my fervent wish that A subtyping
of apheresis platelet donors become a standard of
practice by blood collection centers.
Summary
Platelets express ABO antigens on a large number
of platelet glycoproteins and glycolipids. The amount
of ABO antigen expressed on individual donor platelets
is heterogeneous and determined by genetic and
epigenetic factors. Routine transfusion of ABO-
incompatible platelets can be associated with
cumulative adverse effects including decreased
posttransfusion recovery, increased platelet utilization,
incompatible platelet crossmatches, HLA alloim-
munization, and ABH-specific refractoriness. Out-of-
group platelet transfusion can also be associated
with adverse effects including decreasing platelet
increments and, rarely, severe HTRs. Out-of-group
platelet transfusion may have more severe
consequences in ABO-mismatched bone marrow
transplant patients, who are at increased risk for
significant morbidity and mortality because of ABO
incompatibility.
ABO-identical platelets should be provided
whenever possible, particularly for patients requiring
long-term transfusion support. In patients undergoing
ABO-mismatched transplants, provision of A2 platelets
may be preferable. In patients requiring HLA-antigen
negative and HLA-matched platelets,HLA matching has
priority; however, the ABO compatibility of HLA
platelets should be recorded and considered when
assessing the success or failure of HLA platelets. ABO
compatibility should always be considered when
evaluating and monitoring patients with clinical
refractoriness, particularly group O patients who have
higher mean isohemagglutinin titers.
In neonates and young children, only ABO-identical
or plasma-compatible platelets should be transfused.102
In surgical and other patients with short-term
transfusion needs, ABO compatibility is less of a
concern. ABO-identical or plasma-compatible platelets
should be transfused if available; however, an actively
bleeding patient should never be denied a platelet
transfusion because of ABO compatibility. The risks of
bleeding and the need to achieve hemostasis outweigh
the potential adverse consequences of transfusing an
ABO-incompatible platelet. One potential exception is
ABO-incompatible organ transplantation, in which
plasma containing donor-reactive isoagglutinins should
be avoided. In the postoperative period, donor-
compatible platelets may be considered to minimize
immune stimulation of recipient isoagglutinins.
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